ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, is a highly aggressive subtype unresponsive to endocrine and targeted therapies [1–4].